I am particularly interested in osteosarcoma (OS) research because the cause of disease is unknown in the majority of cases. In addition, the treatment of OS, which usually involves chemotherapy, surgery and radiation therapy, has not been improved over the past twenty years highlighting the need for further research. We have already discovered a new biomarker for OS that can identify the disease early, as well as accurately monitor disease progression. Further, this provides a novel treatment target for OS using gene therapy, which I will be working on during my PhD.

Emel has already published a paper looking at the possible association between osteosarcoma and the LEPROT gene, which could be considered as a potential biomarker for osteosarcoma.

View the paper here

We published an in-depth interview with Dr Rothzerg in August 2023 which can be read here.